【讨论】关于俄罗斯今年上市的一个新药？Ingavirin® - drug destined for new direction in the flu therapy Three months ago one of the largest Russian pharmaceutical company Valenta have launched new antiviral product. Ingavirin® – original innovative domestic product developed by Russian scientists including military virologists under supervision of the Chief Therapist of Russian Federation, Academician of RAS Alexander G. Chuchalin. Product was registered in August, 2008 and was presented in the market in January 2009. Registration certificate LSR – 006330/08. High antiviral efficacy was showed in the trials in vitro and in vivo to the A grippe (subtypes H3N2, H1N1, H5N1), experimental B virus, adenoviruses. Ingavirin® suppresses virus replication in the nuclear stage of the cycle. Antiviral efficacy of Ingavirin® to A virus is realized by the inhibition of the newly synthesized viral NP-protein migration from cytoplasm to nucleus, which is necessary for the infectious process in the infected cells. In distinction from the existing products aimed for the flu treatment Ingavirin is operating to the new protein target - NP-protein. Ingavirin is the only antiviral product providing cell protection by the abruption of the virus multiplication. Expectancy of the resistance evolution is extremely small. Clinical trials of Ingavirin® within I, II, III phases of trials were fulfilled in the specialized research centers of Russia under guidance of Professor of the Ivanovsky Scientific Institute of Virology Kolobukhina L.V. High curative efficacy and safety was proven.查看更多
第1天
关注盖德视界
添加小助手
